Rinkel injection therapy: a multicenter controlled study

Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double‐blind, placebo‐controlled study

“…Eleven studies showed a positive and statistically significant outcome in a total of 306 actively treated patients as compared with 194 treated with placebo whereas two studies failed to show any advantage of the active therapy (93 patients) as compared with placebo (86 patients). However, the two latter studies were conducted according to the socalled Rinkel method, i.e with very low amounts of allergen in the range 0.019-0.15 mg of Amb a 1 (formerly called Ag E) as maintenance dose [20,21]. Other investigators have shown in other trials that significant changes in mediator release after specific nasal challenge begins when a dose of Amb a 1 in the range 0.22-0.6 mg had been reached [22,23], whereas a significant clinical improvement took place with a maintenance dose of 1.94 mg of Amb a 1 [24].…”

Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite

“…There is controversy about the value of limiting dilution desensitization {also called the Miller technique or provocation/neutralization). The literature on this subject has been well reviewed recently by Freed [24], who concludes that there are now more scientifically based favourable reports than unfavourable ones, The negative studies of low dose desensitization to ragweed by Hirsch [25] and Van Mettre [26.27] used a different technique (Rinkel) employing doses of antigen some 5-125 times higher given by a different route (subcutaneous injection). These studies are therefore not comparable to this one.…”

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

“…• mixtures of related, cross-reacting allergen vaccines such as grass-pollen vaccines, deciduous-tree pollen vaccines, related ragweed pollen vaccines and related mite vaccines or • mixtures of other allergen vaccines provided that stability data (1641) (1645)(1646)(1647) and high doses of allergen vaccines may induce a high and unacceptable rate of systemic reactions (1647). Thus, optimal doses using vaccines labeled either in biological units or in mass of major allergens have been proposed (1193).…”